{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Elevation Oncology, Inc."},"Symbol":{"label":"Symbol","value":"ELEV"},"Address":{"label":"Address","value":"888 SEVENTH AVENUE,12TH FLOOR, NEW YORK, New York, 10106, United States"},"Phone":{"label":"Phone","value":"+1 716 371-1125"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition."},"CompanyUrl":{"label":"Company Url","value":"https://www.elevationoncology.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"David Dornan","title":"Chief Scientific Officer"},{"name":"Joseph J. Ferra","title":"President, Chief Executive Officer & Director"},{"name":"Valerie Malyvanh Jansen","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}